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FIGURE 1. Meta-analysis of 2 trials comparing the effect in cardiac surgery on surgical site infection incidence of inserting a gentamicin implant before
wound closure versus no insertion of a gentamicin implant. CI, Confidence interval; OR, odds ratio.
Letters to the Editor3. We absolutely agree with Osawa
and Orii1 that in reality many
surgeons use antibiotics locally,
and that antibiotic use plays an
essential part in many different
methods to reduce sternal wound
infection.
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MASTER PREDICTIVE
MEDIATORS OF THE
POSTCARDIOPULMONARY
BYPASS INFLAMMATORY
RESPONSE
To the Editor:
We read with great interest the well-
documented work of Jouan and col-
leagues1 on gene polymorphism and
cytokine plasma levels as predictive
factors of complications after cardio-
pulmonary bypass (CPB). Previous
studies highlighted potential roles of
cytokines (eg, interleukin [IL]-6 and
-10) on post-CPB complications2,3
but without mechanistic explanations
of these elevated productions. The
interesting andwell-documented study
of Jouan and colleagues1 now gives
this mechanistic explanation. Genetic
testing of IL6-572G>C and IL10-
592C>Amight thus be a tool for iden-
tifying patients at the highest risk of
poor tolerance to the post-CPB inflam-
matory response. Another main inter-
est of this study is to bring some
doubts concerning the role (if any) of
other pro- or anti-inflammatory com-
pounds released during CPB, such as
angiogenic growth factors and lipidic
mediators, on post-CPB adverse
effects.4,5 It is clear that IL-6 and IL-
10 now can be considered as themaster
predictive control mediators of the
post-CPB inflammatory response.of Thoracic and Cardiovascular SurgeYves Denizot, PhDa
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We appreciate the comments of
Denizot and Nathan on our article
‘‘Gene Polymorphisms and Cytokine
Plasma Levels as Predictive Factors
of Complications After Cardiopulmo-
nary Bypass.’’1 However, even if wery c Volume 144, Number 3 743
Letters to the Editorhave demonstrated that genetic testing
is a useful tool for identifying a high-
risk population with a systemic in-
flammatory response syndrome after
cardiopulmonary bypass (CPB), we
would temper the assumption that
‘‘IL-6 and IL-10 now can be consid-
ered as the master predictive control
mediators of the post-CPB inflamma-
tory response’’ because of the multi-
plicity of the intermingled pathways
involved in that response2 and our
obvious inability to explore the ge-
netic determinants of all of them. Fur-
ther clinical investigations with larger
cohorts are clearly needed to pre-
cisely identify the specific contribu-
tion of interleukin-6 and -10 to each
of the clinical complications compos-
ing our clinical end point and to
unravel potential other mediators
that could also modulate the CPB-
induced inflammatory response, such
as chemokines that are currently un-
der investigation andmay be potential
therapeutic targets in the prevention
of systemic inflammatory response
syndrome.3
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WITH BRONCHOALVEOLAR
FEATURES: A POPULATION-
BASED EVALUATION OF THE
EXTENT OF RESECTION IN
BRONCHOALVEOLAR CELL
CARCINOMA
To the Editor:
The article by Whitson and
colleagues1 in the March 2012 issue
has what appears to be an error that
would benefit from clarification.
In the Methods section of their
article, they state that the time period
of interest for the evaluation of overall
and cancer-specific survival is from
1988 to 2007. In the first analysis they
compare those patients undergoing lo-
bectomy with those undergoing an un-
specified sublobar resection. They then
undertake a second analysis of those
patients undergoing specific types of
sublobar resection (wedge and seg-
mentectomy). To undertake this second
analysis, they state that only data from
1998 to 2007 are included as the neces-
sary information is only available in
patients undergoing surgery after 1998.
However, on inspection of their ta-
bles and figures it appears that in
both sets of analysis there are 5532 pa-
tients undergoing lobectomy. It cannot
be the case that there were 5532 lobec-
tomies from 1988 to 2007 and 5532
patients undergoing lobectomy from
1998 to 2007. It appears that their
analysis included patients undergoing
lobectomy from 1988 to 2007 and
those undergoing sublobar resection
from 1997 to 2007, that is, the 2
groups are not contemporaneous.
Is this an error? If not an error, how
do the authors justify this analysis
as these 2 populations are not
comparable?
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We thank Dr Srinathan for his
thoughtful review of our article. His
review has raised a valid question re-
garding the analysis. It would seem
that our description of the dataset
used was not as clear as we had
intended, and we offer this
clarification.
We limited our analysis to data col-
lected from January 1, 1988 (the year
Surveillance, Epidemiology, and End-
Results [SEER] registries began col-
lecting American Joint Committee
on Cancer staging data), through De-
cember 31, 2007. Because the SEER
registries did not differentiate be-
tween the various types of sublobar re-
sections (ie, wedge resections and
segmentectomies) until 1998, our sur-
vival analysis for wedge resections
and segmentectomies is limited to
data obtained from January 1, 1998,
through December 31, 2007. The pub-
lished graphs and tables display data
comparing survivals after wedge re-
section and segmentectomy (1998
through 2007) with survivals after lo-
bectomy (1988 through 2007).1
When we limited our analysis (for
all groups) to data obtained from Jan-
uary 1, 1998, through December 31,
2007, our results were unchanged.
By Kaplan-Meier analysis, we
noted significantly better overall
(P < .0001) and cancer-specific
survivals (P<.0001) after lobectomy
(n ¼ 3846) and segmentectomy
(n ¼ 152) as compared with wedge
resections (n ¼ 768). There was no
significant difference between the sur-
vivals of patients who underwent lo-
bectomies as compared with those
who underwent segmentectomies.
After adjusting for potential con-
founding covariates (using the same
Cox proportional hazards regression2
